Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Research And Development Expenses	$ 4,905,678	$ 3,590,053
Terms of license Agreement	Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma & HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines
Deferred Revenue	$ 10,000,000.0
Cash and cash equivalents	10,010,878		$ 10,867,050
Amount held in money market account	3,300,000
Accounts receivable	118,592		$ 72,609
Cash and cash equivalent [Member]
Cash and cash equivalents	10,000,000.0
Research And Development Expenses [Member]
Research And Development Expenses	$ 4,900,000	$ 3,600,000
Warrants And Options [Member]
Potentially Dilutive Securities Excluded From The Computation Of Eps	7,471,588